Compare Enphase Energy Inc (ENPH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Enphase Energy Inc trades at $32.81 (market cap $4.35B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.3× Enphase Energy Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ENPH | XBI | |
|---|---|---|
Market Cap | $4.35B | $10.11B |
Volume | 5,068,595 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $72.33 | $169.55 |
52-Week Low | $26.12 | $104.99 |
Typical Hold Time | 72 Days | 38 Days |
Enterprise Value | $3.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.91, down 1.76% amid bearish technical signals and mixed earnings performance. The stock faces headwinds from solar sector volatility but maintains solid fundamentals with 46.95% gross margins and positive cash flow. Recent developments include IQ Meter Collar utility approvals and solid-state transformer advancements for AI data centers, providing potential growth catalysts despite recent earnings misses.
The outlook remains cautious with analyst consensus at $42.90 offering 30% upside potential, though technical indicators suggest near-term pressure. Key risks include solar industry financing challenges and competitive threats, while institutional sentiment shows modest optimism with 42% buy ratings. The stock presents a growth opportunity for investors comfortable with sector volatility and execution risks.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
